Literature DB >> 21674175

Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage.

Kengo Tomita1, Toshiaki Teratani, Hirokazu Yokoyama, Takahiro Suzuki, Rie Irie, Hirotoshi Ebinuma, Hidetsugu Saito, Ryota Hokari, Soichiro Miura, Toshifumi Hibi.   

Abstract

BACKGROUND AND AIMS: The similarity of alcoholic liver disease and nonalcoholic steatohepatitis (NASH) in terms of pathogenic mechanisms suggests that immunoglobulin A (IgA) may play an important role in the pathogenesis of NASH. We aimed to determine whether serum IgA concentrations allow a diagnosis of liver fibrosis in NASH.
METHODS: We compared serum IgA concentrations between 108 patients with stages 0-2 NASH and 19 patients with stage 3 NASH.
RESULTS: In a univariate analysis, age (P < 0.0001), gender (P = 0.0039), serum albumin level (P = 0.0192), AST (P < 0.0001), AST/ALT ratio (P < 0.0001), platelet count (P = 0.0027), hyaluronic acid level (P < 0.0001), fasting blood sugar (FBS) (P = 0.0013), IRI (P = 0.0001), prothrombin time (%) (P = 0.0287), IgA (P < 0.0001), total sum of IgG, IgA, and IgM (P = 0.0049), and IgA/(IgG + IgA + IgM) (P = 0.0105) were significantly elevated in severe-stage NASH patients compared with the early-stage NASH group. Multiple logistic regression analysis showed that in severe-stage NASH patients, only serum IgA concentrations were significantly elevated (P = 0.0225) relative to early-stage NASH patients. The area under the curve (AUC) of serum IgA concentrations was 0.758 for detecting severe-stage NASH compared with early-stage NASH.
CONCLUSIONS: Serum IgA concentration could be a useful independent predictor for assessing the pre-cirrhotic progression of NASH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674175     DOI: 10.1007/s10620-011-1771-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Common pathogenic mechanisms in ASH and NASH.

Authors:  Hiromasa Ishii
Journal:  Hepatol Res       Date:  2004-01       Impact factor: 4.288

2.  The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve.

Authors:  Neil J Perkins; Enrique F Schisterman
Journal:  Am J Epidemiol       Date:  2006-01-12       Impact factor: 4.897

3.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

4.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

5.  Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells.

Authors:  K Olas; H Butterweck; W Teschner; H P Schwarz; B Reipert
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

6.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

7.  Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Hiroshi Sakugawa; Tomofumi Nakayoshi; Kasen Kobashigawa; Tsuyoshi Yamashiro; Tatsuji Maeshiro; Satoru Miyagi; Joji Shiroma; Akiyo Toyama; Tomokuni Nakayoshi; Fukunori Kinjo; Atsushi Saito
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

8.  Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll-like receptor 9 activation.

Authors:  B Massonnet; A Delwail; J-M Ayrault; C Chagneau-Derrode; J-C Lecron; C Silvain
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

9.  Immunoglobulin A in the diagnosis of alcoholic liver disease.

Authors:  A van de Wiel; J van Hattum; H J Schuurman; L Kater
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

10.  Hepatic fibrosis produced in guinea pigs by chronic ethanol administration and immunization with acetaldehyde adducts.

Authors:  H Yokoyama; S Nagata; S Moriya; S Kato; T Ito; K Kamegaya; H Ishii
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

View more
  7 in total

1.  Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Iradj Maleki; Mahmood Reza Aminafshari; Tarang Taghvaei; Vahid Hosseini; Alireza Rafiei; Zhila Torabizadeh; Maryam Barzin; Elahe Orang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  Biomarkers in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Lawrence B Cohen; Radu M Nanau
Journal:  Can J Gastroenterol Hepatol       Date:  2014-12

3.  Serum immunoglobulin A levels and non-alcoholic fatty liver disease.

Authors:  Evan Elias; Julia Uhanova; Qian Li; Manna Zhang; Gerald Minuk
Journal:  Can Liver J       Date:  2018-12-25

4.  Serum Immunoglobulin A Levels Do Not Correlate With Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Marialena Mouzaki; Kristin Bramlage; Ana Catalina Arce-Clachar; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-11       Impact factor: 2.839

5.  Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.

Authors:  Christian Rupp; Alexander Rössler; Taotao Zhou; Conrad Rauber; Kilian Friedrich; Andreas Wannhoff; Karl-Heinz Weiss; Peter Sauer; Peter Schirmacher; Caner Süsal; Wolfgang Stremmel; Daniel N Gotthardt
Journal:  United European Gastroenterol J       Date:  2017-06-17       Impact factor: 4.623

6.  Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease.

Authors:  Tim Hendrikx; Martin L Watzenböck; Sofie M A Walenbergh; Shahzada Amir; Sabrina Gruber; Maria Ozsvar Kozma; Heike I Grabsch; Ger H Koek; Marieke J Pierik; Katharina Staufer; Michael Trauner; Satish C Kalhan; Daisy Jonkers; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov
Journal:  BMC Med       Date:  2016-07-22       Impact factor: 8.775

Review 7.  Immunoglobulin A and liver diseases.

Authors:  Tatsuo Inamine; Bernd Schnabl
Journal:  J Gastroenterol       Date:  2017-10-26       Impact factor: 7.527

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.